請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20483
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳青周 | |
dc.contributor.author | Pin-Jyun Chen | en |
dc.contributor.author | 陳品君 | zh_TW |
dc.date.accessioned | 2021-06-08T02:50:17Z | - |
dc.date.copyright | 2017-09-14 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-16 | |
dc.identifier.citation | Adra, Chaker N., Jon Ko, David Leonard, Lori J. Wirth, Richard A. Cerione, and Bing Lim. 1993. 'Identification of a novel protein with GDP dissociation inhibitor activity for the ras-like proteins CDC42Hs and Rac 1', Genes, Chromosomes and Cancer, 8: 253-61.
Allis, C. David, and Thomas Jenuwein. 2016. 'The molecular hallmarks of epigenetic control', Nat Rev Genet, 17: 487-500. Arumugam, T., V. Ramachandran, K. F. Fournier, H. Wang, L. Marquis, J. L. Abbruzzese, G. E. Gallick, C. D. Logsdon, D. J. McConkey, and W. Choi. 2009. 'Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer', Cancer Res, 69: 5820-8. Aznar, S., and J. C. Lacal. 2001. 'Rho signals to cell growth and apoptosis', Cancer Lett, 165: 1-10. Barcellos-Hoff, M. H., D. Lyden, and T. C. Wang. 2013. 'The evolution of the cancer niche during multistage carcinogenesis', Nat Rev Cancer, 13: 511-8. Baselga, José, and Neal Rosen. 2008. 'Determinants of RASistance to Anti–Epidermal Growth Factor Receptor Agents', Journal of Clinical Oncology, 26: 1582-84. Bender, E. 2014. 'Epidemiology: The dominant malignancy', Nature, 513: S2-3. Bethune, G., D. Bethune, N. Ridgway, and Z. Xu. 2010. 'Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update', J Thorac Dis, 2: 48-51. Bloushtain-Qimron, N., J. Yao, E. L. Snyder, M. Shipitsin, L. L. Campbell, S. A. Mani, M. Hu, H. Chen, V. Ustyansky, J. E. Antosiewicz, P. Argani, M. K. Halushka, J. A. Thomson, P. Pharoah, A. Porgador, S. Sukumar, R. Parsons, A. L. Richardson, M. R. Stampfer, R. S. Gelman, T. Nikolskaya, Y. Nikolsky, and K. Polyak. 2008. 'Cell type-specific DNA methylation patterns in the human breast', Proc Natl Acad Sci U S A, 105: 14076-81. Bonnet, D., and J. E. Dick. 1997. 'Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell', Nat Med, 3: 730-7. Brabletz, S., K. Bajdak, S. Meidhof, U. Burk, G. Niedermann, E. Firat, U. Wellner, A. Dimmler, G. Faller, J. Schubert, and T. Brabletz. 2011. 'The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells', Embo j, 30: 770-82. Brugger, W., N. Triller, M. Blasinska-Morawiec, S. Curescu, R. Sakalauskas, G. M. Manikhas, J. Mazieres, R. Whittom, C. Ward, K. Mayne, K. Trunzer, and F. Cappuzzo. 2011. 'Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer', J Clin Oncol, 29: 4113-20. Chan, B. A., and B. G. M. Hughes. 2015. 'Targeted therapy for non-small cell lung cancer: current standards and the promise of the future', Transl Lung Cancer Res, 4: 36-54. Charafe-Jauffret, E., F. Monville, C. Ginestier, G. Dontu, D. Birnbaum, and M. S. Wicha. 2008. 'Cancer stem cells in breast: current opinion and future challenges', Pathobiology, 75: 75-84. Cheng, T. Y., S. M. Cramb, P. D. Baade, D. R. Youlden, C. Nwogu, and M. E. Reid. 2016. 'The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics', J Thorac Oncol, 11: 1653-71. Cho, H. J., K. E. Baek, and J. Yoo. 2010. 'RhoGDI2 as a therapeutic target in cancer', Expert Opin Ther Targets, 14: 67-75. Collins, A. T., P. A. Berry, C. Hyde, M. J. Stower, and N. J. Maitland. 2005. 'Prospective identification of tumorigenic prostate cancer stem cells', Cancer Res, 65: 10946-51. Dejeux, E., J. A. Ronneberg, H. Solvang, I. Bukholm, S. Geisler, T. Aas, I. G. Gut, A. L. Borresen-Dale, P. E. Lonning, V. N. Kristensen, and J. Tost. 2010. 'DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response', Mol Cancer, 9: 68. Ding, L., T. L. Saunders, G. Enikolopov, and S. J. Morrison. 2012. 'Endothelial and perivascular cells maintain haematopoietic stem cells', Nature, 481: 457-62. Ding, Lei, and Sean J. Morrison. 2013. 'Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches', Nature, 495: 231-35. Dransart, E., B. Olofsson, and J. Cherfils. 2005. 'RhoGDIs revisited: novel roles in Rho regulation', Traffic, 6: 957-66. Duester, G. 1998. 'Alcohol dehydrogenase as a critical mediator of retinoic acid synthesis from vitamin A in the mouse embryo', J Nutr, 128: 459s-62s. Eberhard, D. A., B. E. Johnson, L. C. Amler, A. D. Goddard, S. L. Heldens, R. S. Herbst, W. L. Ince, P. A. Janne, T. Januario, D. H. Johnson, P. Klein, V. A. Miller, M. A. Ostland, D. A. Ramies, D. Sebisanovic, J. A. Stinson, Y. R. Zhang, S. Seshagiri, and K. J. Hillan. 2005. 'Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib', J Clin Oncol, 23: 5900-9. Eden, S., T. Hashimshony, I. Keshet, H. Cedar, and A. W. Thorne. 1998. 'DNA methylation models histone acetylation', Nature, 394: 842-42. Ekstrand, A. J., N. Sugawa, C. D. James, and V. P. Collins. 1992. 'Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails', Proc Natl Acad Sci U S A, 89: 4309-13. Eramo, A., F. Lotti, G. Sette, E. Pilozzi, M. Biffoni, A. Di Virgilio, C. Conticello, L. Ruco, C. Peschle, and R. De Maria. 2008. 'Identification and expansion of the tumorigenic lung cancer stem cell population', Cell Death Differ, 15: 504-14. Frisch, S. M., and R. A. Screaton. 2001. 'Anoikis mechanisms', Curr Opin Cell Biol, 13: 555-62. Gentles, A. J., A. M. Newman, C. L. Liu, S. V. Bratman, W. Feng, D. Kim, V. S. Nair, Y. Xu, A. Khuong, C. D. Hoang, M. Diehn, R. B. West, S. K. Plevritis, and A. A. Alizadeh. 2015. 'The prognostic landscape of genes and infiltrating immune cells across human cancers', Nat Med, 21: 938-45. Gildea, J. J., M. J. Seraj, G. Oxford, M. A. Harding, G. M. Hampton, C. A. Moskaluk, H. F. Frierson, M. R. Conaway, and D. Theodorescu. 2002. 'RhoGDI2 is an invasion and metastasis suppressor gene in human cancer', Cancer Res, 62: 6418-23. Gomez del Pulgar, T., S. A. Benitah, P. F. Valeron, C. Espina, and J. C. Lacal. 2005. 'Rho GTPase expression in tumourigenesis: evidence for a significant link', Bioessays, 27: 602-13. Gong, Y., E. Yao, R. Shen, A. Goel, M. Arcila, J. Teruya-Feldstein, M. F. Zakowski, S. Frankel, M. Peifer, R. K. Thomas, M. Ladanyi, and W. Pao. 2009. 'High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)', PLoS One, 4. Gschwind, Andreas, Oliver M. Fischer, and Axel Ullrich. 2004. 'The discovery of receptor tyrosine kinases: targets for cancer therapy', Nat Rev Cancer, 4: 361-70. Han, B., N. Bhowmick, Y. Qu, S. Chung, A. E. Giuliano, and X. Cui. 2017. 'FOXC1: an emerging marker and therapeutic target for cancer', Oncogene. Han, B., Y. Qu, Y. Jin, Y. Yu, N. Deng, K. Wawrowsky, X. Zhang, N. Li, S. Bose, Q. Wang, S. Sakkiah, R. Abrol, T. W. Jensen, B. P. Berman, H. Tanaka, J. Johnson, B. Gao, J. Hao, Z. Liu, R. Buttyan, P. S. Ray, M. C. Hung, A. E. Giuliano, and X. Cui. 2015. 'FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer', Cell Rep, 13: 1046-58. Hardavella, G., R. George, and T. Sethi. 2016. 'Lung cancer stem cells—characteristics, phenotype', Transl Lung Cancer Res, 5: 272-9. Hermann, P. C., S. L. Huber, T. Herrler, A. Aicher, J. W. Ellwart, M. Guba, C. J. Bruns, and C. Heeschen. 2007. 'Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer', Cell Stem Cell, 1: 313-23. Ho, M. M., A. V. Ng, S. Lam, and J. Y. Hung. 2007. 'Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells', Cancer Res, 67: 4827-33. Honegger, A. M., T. J. Dull, S. Felder, E. Van Obberghen, F. Bellot, D. Szapary, A. Schmidt, A. Ullrich, and J. Schlessinger. 1987. 'Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing', Cell, 51: 199-209. Hu, L. D., H. F. Zou, S. X. Zhan, and K. M. Cao. 2007. 'Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis', Oncol Rep, 17: 1383-9. Huang, R. Y., M. K. Wong, T. Z. Tan, K. T. Kuay, A. H. Ng, V. Y. Chung, Y. S. Chu, N. Matsumura, H. C. Lai, Y. F. Lee, W. J. Sim, C. Chai, E. Pietschmann, S. Mori, J. J. Low, M. Choolani, and J. P. Thiery. 2013. 'An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)', Cell Death Dis, 4: e915. Huber, M. A., N. Kraut, and H. Beug. 2005. 'Molecular requirements for epithelial-mesenchymal transition during tumor progression', Curr Opin Cell Biol, 17: 548-58. Hynes, Nancy E., and Heidi A. Lane. 2005. 'ERBB receptors and cancer: the complexity of targeted inhibitors', Nat Rev Cancer, 5: 341-54. Janku, Filip, David J. Stewart, and Razelle Kurzrock. 2010. 'Targeted therapy in non-small-cell lung cancer[mdash]is it becoming a reality?', Nat Rev Clin Oncol, 7: 401-14. Jin, Y., B. Han, J. Chen, R. Wiedemeyer, S. Orsulic, S. Bose, X. Zhang, B. Y. Karlan, A. E. Giuliano, Y. Cui, and X. Cui. 2014. 'FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer', Ann Surg Oncol, 21 Suppl 4: S758-66. Kaestner, K. H., W. Knochel, and D. E. Martinez. 2000. 'Unified nomenclature for the winged helix/forkhead transcription factors', Genes Dev, 14: 142-6. Kalluri, R. 2009. 'The basics of epithelial-mesenchymal transition', 119: 1420-8. Kohno, T., T. Nakaoku, K. Tsuta, K. Tsuchihara, S. Matsumoto, K. Yoh, and K. Goto. 2015. 'Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer', Transl Lung Cancer Res, 4: 156-64. Kondo, T., T. Setoguchi, and T. Taga. 2004. 'Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line', Proc Natl Acad Sci U S A, 101: 781-6. Kreso, A., and C. A. O'Brien. 2008. 'Colon cancer stem cells', Curr Protoc Stem Cell Biol, Chapter 3: Unit 3.1. Kume, T., K. Deng, and B. L. Hogan. 2000. 'Murine forkhead/winged helix genes Foxc1 (Mf1) and Foxc2 (Mfh1) are required for the early organogenesis of the kidney and urinary tract', Development, 127: 1387-95. Kume, T., H. Y. Jiang, J. M. Topczewska, and B. L. M. Hogan. 2001. 'The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis', Genes Dev, 15: 2470-82. Lee, J. M., S. Dedhar, R. Kalluri, and E. W. Thompson. 2006. 'The epithelial-mesenchymal transition: new insights in signaling, development, and disease', J Cell Biol, 172: 973-81. Lehmann, O. J., J. C. Sowden, P. Carlsson, T. Jordan, and S. S. Bhattacharya. 2003. 'Fox's in development and disease', Trends Genet, 19: 339-44. Levkowitz, G., H. Waterman, E. Zamir, Z. Kam, S. Oved, W. Y. Langdon, L. Beguinot, B. Geiger, and Y. Yarden. 1998. 'c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor', Genes Dev, 12: 3663-74. Li, J., Z. C. Feng, F. S. Yeung, M. R. Wong, A. Oakie, G. F. Fellows, C. G. Goodyer, D. A. Hess, and R. Wang. 2014. 'Aldehyde dehydrogenase 1 activity in the developing human pancreas modulates retinoic acid signalling in mediating islet differentiation and survival', Diabetologia, 57: 754-64. Li, X., M. T. Lewis, J. Huang, C. Gutierrez, C. K. Osborne, M. F. Wu, S. G. Hilsenbeck, A. Pavlick, X. Zhang, G. C. Chamness, H. Wong, J. Rosen, and J. C. Chang. 2008. 'Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy', J Natl Cancer Inst, 100: 672-9. Liao, B. C., C. C. Lin, and J. C. Yang. 2015. 'Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer', Curr Opin Oncol, 27: 94-101. Lin, Y. C., Y. C. Lin, J. Y. Shih, W. J. Huang, S. W. Chao, Y. L. Chang, and C. C. Chen. 2015. 'DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers', Clin Cancer Res, 21: 428-38. Lobo, N. A., Y. Shimono, D. Qian, and M. F. Clarke. 2007. 'The biology of cancer stem cells', Annu Rev Cell Dev Biol, 23: 675-99. Lynch , Thomas J., Daphne W. Bell , Raffaella Sordella , Sarada Gurubhagavatula , Ross A. Okimoto , Brian W. Brannigan , Patricia L. Harris , Sara M. Haserlat , Jeffrey G. Supko , Frank G. Haluska , David N. Louis , David C. Christiani , Jeff Settleman , and Daniel A. Haber 2004. 'Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib', New England Journal of Medicine, 350: 2129-39. Ma, L., G. Xu, A. Sotnikova, M. Szczepanowski, M. Giefing, K. Krause, M. Krams, R. Siebert, J. Jin, and W. Klapper. 2007. 'Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma', Br J Haematol, 139: 217-23. Malanchi, I., H. Peinado, D. Kassen, T. Hussenet, D. Metzger, P. Chambon, M. Huber, D. Hohl, A. Cano, W. Birchmeier, and J. Huelsken. 2008. 'Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling', Nature, 452: 650-3. Mani, S. A., W. Guo, M. J. Liao, E. N. Eaton, A. Ayyanan, A. Y. Zhou, M. Brooks, F. Reinhard, C. C. Zhang, M. Shipitsin, L. L. Campbell, K. Polyak, C. Brisken, J. Yang, and R. A. Weinberg. 2008. 'The epithelial-mesenchymal transition generates cells with properties of stem cells', Cell, 133: 704-15. Midha, A., S. Dearden, and R. McCormack. 2015. 'EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)', Am J Cancer Res, 5: 2892-911. Moissoglu, K., K. S. McRoberts, J. A. Meier, D. Theodorescu, and M. A. Schwartz. 2009. 'Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases', Cancer Res, 69: 2838-44. Morgillo, F., C. M. Della Corte, M. Fasano, and F. Ciardiello. 2016. 'Mechanisms of resistance to EGFR-targeted drugs: lung cancer', ESMO Open, 1. Moscatello, D. K., M. Holgado-Madruga, A. K. Godwin, G. Ramirez, G. Gunn, P. W. Zoltick, J. A. Biegel, R. L. Hayes, and A. J. Wong. 1995. 'Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors', Cancer Res, 55: 5536-9. Myatt, S. S., and E. W. Lam. 2007. 'The emerging roles of forkhead box (Fox) proteins in cancer', Nat Rev Cancer, 7: 847-59. Nieto, M. A., R. Y. Huang, R. A. Jackson, and J. P. Thiery. 2016. 'EMT: 2016', Cell, 166: 21-45. Nishimura, D. Y., R. E. Swiderski, W. L. Alward, C. C. Searby, S. R. Patil, S. R. Bennet, A. B. Kanis, J. M. Gastier, E. M. Stone, and V. C. Sheffield. 1998. 'The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25', Nat Genet, 19: 140-7. Nobes, C. D., and A. Hall. 1995. 'Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility', Biochem Soc Trans, 23: 456-9. Olofsson, B. 1999. 'Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling', Cell Signal, 11: 545-54. Pao, W., and J. Chmielecki. 2010. 'Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer', Nat Rev Cancer, 10: 760-74. Pao, William, and Katherine E. Hutchinson. 2012. 'Chipping away at the lung cancer genome', Nat Med, 18: 349-51. Pardal, R., M. F. Clarke, and S. J. Morrison. 2003. 'Applying the principles of stem-cell biology to cancer', Nat Rev Cancer, 3: 895-902. Purton, Louise E., Irwin D. Bernstein, and Steven J. Collins. 2000. 'All-trans retinoic acid enhances the long-term repopulating activity of cultured hematopoietic stem cells', Blood, 95: 470-77. Ramalho-Santos, Miguel, Soonsang Yoon, Yumi Matsuzaki, Richard C. Mulligan, and Douglas A. Melton. 2002. ''Stemness': Transcriptional Profiling of Embryonic and Adult Stem Cells', Science, 298: 597-600. Ray, P. S., J. Wang, Y. Qu, M. S. Sim, J. Shamonki, S. P. Bagaria, X. Ye, B. Liu, D. Elashoff, D. S. Hoon, M. A. Walter, J. W. Martens, A. L. Richardson, A. E. Giuliano, and X. Cui. 2010a. 'FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer', Cancer Res, 70: 3870-6. Ray, Partha S., Jinhua Wang, Ying Qu, Myung-Shin Sim, Jaime Shamonki, Sanjay P. Bagaria, Xing Ye, Bingya Liu, David Elashoff, Dave S. Hoon, Michael A. Walter, John W. Martens, Andrea L. Richardson, Armando E. Giuliano, and Xiaojiang Cui. 2010b. 'FOXC1 Is a Potential Prognostic Biomarker with Functional Significance in Basal-like Breast Cancer', Cancer Research, 70: 3870-76. Reya, Tannishtha, Sean J. Morrison, Michael F. Clarke, and Irving L. Weissman. 2001. 'Stem cells, cancer, and cancer stem cells', Nature, 414: 105-11. Riely, G. J., M. G. Kris, D. Rosenbaum, J. Marks, A. Li, D. A. Chitale, K. Nafa, E. R. Riedel, M. Hsu, W. Pao, V. A. Miller, and M. Ladanyi. 2008. 'Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma', Clin Cancer Res, 14: 5731-4. Riely, G. J., J. Marks, and W. Pao. 2009. 'KRAS mutations in non-small cell lung cancer', Proc Am Thorac Soc, 6: 201-5. Rossman, Kent L., Channing J. Der, and John Sondek. 2005. 'GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors', Nat Rev Mol Cell Biol, 6: 167-80. Said, N., M. Sanchez-Carbayo, S. C. Smith, and D. Theodorescu. 2012. 'RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration', J Clin Invest, 122: 1503-18. Saleem, R. A., S. Banerjee-Basu, T. C. Murphy, A. Baxevanis, and M. A. Walter. 2004. 'Essential structural and functional determinants within the forkhead domain of FOXC1', Nucleic Acids Res, 32: 4182-93. Sayan, A. E., T. R. Griffiths, R. Pal, G. J. Browne, A. Ruddick, T. Yagci, R. Edwards, N. J. Mayer, H. Qazi, S. Goyal, S. Fernandez, K. Straatman, G. D. Jones, K. J. Bowman, A. Colquhoun, J. K. Mellon, M. Kriajevska, and E. Tulchinsky. 2009. 'SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer', Proc Natl Acad Sci U S A, 106: 14884-9. Saydam, O., Y. Shen, T. Wurdinger, O. Senol, E. Boke, M. F. James, B. A. Tannous, A. O. Stemmer-Rachamimov, M. Yi, R. M. Stephens, C. Fraefel, J. F. Gusella, A. M. Krichevsky, and X. O. Breakefield. 2009. 'Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway', Mol Cell Biol, 29: 5923-40. Scherle, P., T. Behrens, and L. M. Staudt. 1993. 'Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes', Proc Natl Acad Sci U S A, 90: 7568-72. Schunke, D., P. Span, H. Ronneburg, A. Dittmer, M. Vetter, H. J. Holzhausen, E. Kantelhardt, S. Krenkel, V. Muller, F. C. Sweep, C. Thomssen, and J. Dittmer. 2007. 'Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells', Cancer Res, 67: 10694-702. Sequist, L. V., B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, and J. A. Engelman. 2011. 'Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors', Sci Transl Med, 3: 75ra26. Sharma, Sreenath V., Daphne W. Bell, Jeffrey Settleman, and Daniel A. Haber. 2007. 'Epidermal growth factor receptor mutations in lung cancer', Nat Rev Cancer, 7: 169-81. Sholl, L. M., B. Y. Yeap, A. J. Iafrate, A. J. Holmes-Tisch, Y. P. Chou, M. T. Wu, Y. G. Goan, L. Su, E. Benedittini, J. Yu, M. Loda, P. A. Jänne, D. C. Christiani, and L. R. Chirieac. 2009. 'Lung Adenocarcinoma with EGFR Amplification has Distinct Clinicopathologic and Molecular Features in Never-Smokers', Cancer Res, 69: 8341-8. Siegel, Rebecca L., Kimberly D. Miller, and Ahmedin Jemal. 2017. 'Cancer statistics, 2017', CA: A Cancer Journal for Clinicians, 67: 7-30. Singh, S. K., C. Hawkins, I. D. Clarke, J. A. Squire, J. Bayani, T. Hide, R. M. Henkelman, M. D. Cusimano, and P. B. Dirks. 2004. 'Identification of human brain tumour initiating cells', Nature, 432: 396-401. Sizemore, S. T., and R. A. Keri. 2012. 'The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression', J Biol Chem, 287: 24631-40. Steuer, C. E., F. R. Khuri, and S. S. Ramalingam. 2015. 'The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer', Cancer, 121: E1-6. Stewart, E. L., S. Z. Tan, G. Liu, and M. S. Tsao. 2015. 'Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review', Transl Lung Cancer Res, 4: 67-81. Succony, L., and S. M. Janes. 2014. 'Airway stem cells and lung cancer', Qjm, 107: 607-12. Szasz, A. M., A. Lanczky, A. Nagy, S. Forster, K. Hark, J. E. Green, A. Boussioutas, R. Busuttil, A. Szabo, and B. Gyorffy. 2016. 'Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients', Oncotarget, 7: 49322-33. Tan, C. S., D. Gilligan, and S. Pacey. 2015. 'Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer', Lancet Oncol, 16: e447-59. Tapper, J., E. Kettunen, W. El-Rifai, M. Seppala, L. C. Andersson, and S. Knuutila. 2001. 'Changes in gene expression during progression of ovarian carcinoma', Cancer Genet Cytogenet, 128: 1-6. Taube, Joseph H., Jason I. Herschkowitz, Kakajan Komurov, Alicia Y. Zhou, Supriya Gupta, Jing Yang, Kimberly Hartwell, Tamer T. Onder, Piyush B. Gupta, Kurt W. Evans, Brett G. Hollier, Prahlad T. Ram, Eric S. Lander, Jeffrey M. Rosen, Robert A. Weinberg, and Sendurai A. Mani. 2010. 'Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes', Proceedings of the National Academy of Sciences, 107: 15449-54. Thomson, James A., Joseph Itskovitz-Eldor, Sander S. Shapiro, Michelle A. Waknitz, Jennifer J. Swiergiel, Vivienne S. Marshall, and Jeffrey M. Jones. 1998. 'Embryonic Stem Cell Lines Derived from Human Blastocysts', Science, 282: 1145-47. Thress, K. S., C. P. Paweletz, E. Felip, B. C. Cho, D. Stetson, B. Dougherty, Z. Lai, A. Markovets, A. Vivancos, Y. Kuang, D. Ercan, S. E. Matthews, M. Cantarini, J. C. Barrett, P. A. Janne, and G. R. Oxnard. 2015a. 'Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M', Nat Med, 21. ———. 2015b. 'Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M', Nat Med, 21: 560-2. Tkocz, D., N. T. Crawford, N. E. Buckley, F. B. Berry, R. D. Kennedy, J. J. Gorski, D. P. Harkin, and P. B. Mullan. 2012. 'BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers', Oncogene, 31: 3667-78. Travis, W. D., E. Brambilla, M. Noguchi, A. G. Nicholson, K. R. Geisinger, Y. Yatabe, D. G. Beer, C. A. Powell, G. J. Riely, P. E. Van Schil, K. Garg, J. H. M. Austin, H. Asamura, V. W. Rusch, F. R. Hirsch, G. Scagliotti, T. Mitsudomi, R. M. Huber, Y. Ishikawa, J. Jett, M. Sanchez-Cespedes, J. P. Sculier, T. Takahashi, M. Tsuboi, J. Vansteenkiste, I. Wistuba, P. C. Yang, D. Aberle, C. Brambilla, D. Flieder, W. Franklin, A. Gazdar, M. Gould, P. Hasleton, D. Henderson, B. Johnson, D. Johnson, K. Kerr, K. Kuriyama, J. S. Lee, V. A. Miller, I. Petersen, V. Roggli, R. Rosell, N. Saijo, E. Thunnissen, M. Tsao, and D. Yankelewitz. 2011. 'International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma', J Thorac Oncol, 6: 244-85. Visvader, J. E., and G. J. Lindeman. 2008. 'Cancer stem cells in solid tumours: accumulating evidence and unresolved questions', Nature Reviews Cancer, 8: 755-68. Walter, A. O., R. T. Sjin, H. J. Haringsma, K. Ohashi, J. Sun, K. Lee, A. Dubrovskiy, M. Labenski, Z. Zhu, Z. Wang, M. Sheets, T. St Martin, R. Karp, D. van Kalken, P. Chaturvedi, D. Niu, M. Nacht, R. C. Petter, W. Westlin, K. Lin, S. Jaw-Tsai, M. Raponi, T. Van Dyke, J. Etter, Z. Weaver, W. Pao, J. Singh, A. D. Simmons, T. C. Harding, and A. Allen. 2013. 'Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC', Cancer Discov, 3: 1404-15. Wang, J., P. S. Ray, M. S. Sim, X. Z. Zhou, K. P. Lu, A. V. Lee, X. Lin, S. P. Bagaria, A. E. Giuliano, and X. Cui. 2012. 'FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-kappaB signaling', Oncogene, 31: 4798-802. Wang, Shuhang, Shundong Cang, and Delong Liu. 2016. 'Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer', Journal of Hematology & Oncology, 9: 34. Wang, Shuhang, Stella T. Tsui, Christina Liu, Yongping Song, and Delong Liu. 2016. 'EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer', Journal of Hematology & Oncology, 9: 59. Wang, X., D. Goldstein, P. J. Crowe, and J. L. Yang. 2016. 'Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence', Onco Targets Ther, 9: 5461-73. Wasserman, Wyeth W., and Albin Sandelin. 2004. 'Applied bioinformatics for the identification of regulatory elements', Nat Rev Genet, 5: 276-87. Wei, L. X., R. S. Zhou, H. F. Xu, J. Y. Wang, and M. H. Yuan. 2013. 'High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients', Tumour Biol, 34: 941-6. Weigel, D., G. Jurgens, F. Kuttner, E. Seifert, and H. Jackle. 1989. 'The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo', Cell, 57: 645-58. Wu, J. Y., S. G. Wu, C. H. Yang, C. H. Gow, Y. L. Chang, C. J. Yu, J. Y. Shih, and P. C. Yang. 2008. 'Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response', Clin Cancer Res, 14: 4877-82. Xia, L., W. Huang, D. Tian, H. Zhu, X. Qi, Z. Chen, Y. Zhang, H. Hu, D. Fan, Y. Nie, and K. Wu. 2013. 'Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma', Hepatology, 57: 610-24. Xiao, D., and J. He. 2010. 'Epithelial mesenchymal transition and lung cancer', J Thorac Dis, 2: 154-9. Xu, Y., Q. S. Shao, H. B. Yao, Y. Jin, Y. Y. Ma, and L. H. Jia. 2014. 'Overexpression of FOXC1 correlates with poor prognosis in gastric cancer patients', Histopathology, 64: 963-70. Xu, Y. Y., J. Tian, Q. Hao, and L. R. Yin. 2016. 'MicroRNA-495 downregulates FOXC1 expression to suppress cell growth and migration in endometrial cancer', Tumour Biol, 37: 239-51. Xu, Z. Y., Q. M. Yu, Y. A. Du, L. T. Yang, R. Z. Dong, L. Huang, P. F. Yu, and X. D. Cheng. 2013. 'Knockdown of long non-coding RNA HOTAIR suppresses tumor invasion and reverses epithelial-mesenchymal transition in gastric cancer', Int J Biol Sci, 9: 587-97. Yaish, P., A. Gazit, C. Gilon, and A. Levitzki. 1988. 'Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors', Science, 242: 933-5. Yarden, Y. 2001. 'The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities', Eur J Cancer, 37 Suppl 4: S3-8. Ying, L., Q. Chen, Y. Wang, Z. Zhou, Y. Huang, and F. Qiu. 2012. 'Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition', Mol Biosyst, 8: 2289-94. Yu, H. A. 2013. 'Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR mutant Lung Cancers', 19: 2240-7. Zhang, Y., L. A. R. Rosado, S. Y. Moon, and B. Zhang. 2009. 'Silencing of D4-GDI Inhibits Growth and Invasive Behavior in MDA-MB-231', J Biol Chem, 284: 12956-65. Zhang, Y., and B. Zhang. 2006a. 'D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness', Cancer Res, 66: 5592-8. Zhang, Yaqin, and Baolin Zhang. 2006b. 'D4-GDI, a Rho GTPase Regulator, Promotes Breast Cancer Cell Invasiveness', Cancer Res, 66: 5592-98. Zhao, Y., Q. Guo, J. Chen, J. Hu, S. Wang, and Y. Sun. 2014. 'Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation', Oncol Rep, 31: 358-64. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20483 | - |
dc.description.abstract | EGFR activating mutation在亞洲地區之非小細胞肺癌病患約佔60%,EGFR-TKI可治療這類型之病患,但治療9-12個月後會產生Acquired resistance,因此探討EGFR-TKI抗藥性之機轉以克服抗藥性是重要之課題。
我們發現HCC827/IR (Iressa resistance) 與H1975/AR (AZD9291 resistance) 細胞均具Epithelial mesenchymal transition (EMT) 之特性,即E-cadherin表現降低與Vimentin表現增加、細胞移動能力增加。以RNA sequencing分析兩株抗藥性細胞,發現轉錄因子FOXC1之表現均增加,抑制細胞FOXC1之表現可恢復對TKI之敏感性,細胞之生長速度與遷移能力下降,亦可降低癌幹細胞性質。以Gene ontology分析與細胞遷移相關之基因,發現Rho家族蛋白RhoGDI2在抗藥性細胞表現降低,而抑制FOXC1會增加RhoGDI2之表現,並發現FOXC1會結合至RhoGDI2之promoter,抑制RhoGDI2之表現會增加細胞之遷移能力,顯示FOXC1會透過結合至RhoGDI2之promoter而抑制其表現。以Kaplan Meier Plotter分析肺腺癌病人分別在FOXC1高表現和RhoGDI2低表現中具較差預後。因此,推斷FOXC1可能可成為對抗非小細胞肺癌抗藥性之標的。 | zh_TW |
dc.description.abstract | Epidermal growth factor receptor (EGFR)-activating mutation is the most common driver oncogene in lung adenocarcinoma in East Asia. So far, Tyrosine kinase inhibitors (TKIs) have been regarded as the preferred treatment for advanced lung adenocarcinoma harboring activating mutation in EGFR. However, acquired resistance often develops after treatment within 9-12 months. It is important to elucidate its underlying mechanism to improve the treatment.
We establish two TKI-resistant NSCLC cell lines, and find that the expression of FOXC1, which is a transcriptional factor, is up-regulated in TKIresistant cells. FOXC1 knockdown not only restores the sensitivity to TKI but decreases cell proliferation and migration. FOXC1 knockdown also inhibits the cancer stem cells signature. We further examine several genes that are associated with motility and adhesion in TKI-resistant cell lines, and find that RhoGDI2 is up-regulated and its promoter activity is increased when FOXC1 is knocked down. We also clarify that FOXC1 binds to the promoter region of RhoGDI2 by ChIP assay, and RhoGDI2 knockdown increases cell migration. These data indicate that FOXC1 can bind to the promoter of RhoGDI2 to inhibit its expression. In Kaplan Meier Plotter database, high expression of FOXC1 and low expression of RhoGDI2 are related to poor patients prognosis. Therefore, FOXC1 might be an oncotarget in TKI-resistant NSCLC cells. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T02:50:17Z (GMT). No. of bitstreams: 1 ntu-106-R04443001-1.pdf: 4273840 bytes, checksum: 56af4a7bf682cf0f4845c21d58d0da13 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 縮寫表 2
摘要 6 Abstract 7 第一章 緒論 8 第一節 肺癌 (Lung cancer) 9 第二節 非小細胞肺癌之EGFR標靶治療 (EGFR-targeted therapy in NSCLC) 15 第三節 癌幹細胞 (Cancer stem cell, CSC) 19 第四節 表皮間質轉換作用 (Epithelial mesenchymal transition, EMT) 24 第五節 Forkhead Box Protein C1 (FOXC1) 蛋白 29 第六節 Rho (Rhodopsin) 蛋白家族 32 研究動機 35 第二章 實驗材料與方法 36 第三章 實驗結果 48 第四章 討論 68 第五章 結論 73 參考文獻 75 | |
dc.language.iso | zh-TW | |
dc.title | FOXC1在非小細胞肺癌EGFR-TKI抗藥性之研究 | zh_TW |
dc.title | Role of FOXC1 in EGFR-TKI Resistance of Non-Small Cell Lung Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳明賢,施金元 | |
dc.subject.keyword | 表皮生長因子受體-酪胺酸激?抑制劑,繼發抗藥性,FOXC1蛋白, | zh_TW |
dc.subject.keyword | EGFR-TKI,acquired resistance,FOXC1, | en |
dc.relation.page | 87 | |
dc.identifier.doi | 10.6342/NTU201703677 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2017-08-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 4.17 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。